# Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

## TL;DR

This commentary evaluates the reliability of a new method for finding Alzheimer’s disease biomarkers in cerebrospinal fluid and discusses challenges in applying these findings to patient care.

## Contribution

The paper critically assesses the translational potential and robustness of newly discovered Alzheimer’s biomarkers in cerebrospinal fluid.

## Key findings

- The commentary reviews the method's reliability for identifying diagnostic biomarkers in Alzheimer’s disease.
- It highlights translational challenges in applying these biomarkers to assist Alzheimer’s patients and those at risk.

## Abstract

In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in Alzheimer’s disease (AD). In addition, we examine how these newly discovered and previously discovered biomarkers, can play a role in assisting patients with AD and those at risk for developing AD, with an emphasis on the translational hurdles that accompany such discoveries.